Understand how IVI guidance reduces PCI complications in complex coronary lesions, outperforming angiography alone.

Sacramento surgeon Dr. Inder Singh is helping treat peripheral artery disease with newly FDA-approved removable stents.

The patency rate at 6 months was higher for the silicone-coated metallic stent vs double-J stent. A silicone-covered metallic stent maintains patency better than a double-J stent in patients with ...

“And I've recognized that, wow, the patient complaints that we get that there’s pain with these stents is very real. We're excited to be able to develop an idea and a concept and a product that ...

Joanna J. Wykrzykowska, MD, PhD, associate professor of cardiology at University Medical Center Groningen, Groningen, the Netherlands, said the long-term rates of stent-related adverse events is a ...

Jonathan J. Stent, “Jos”, 54, of New Haven, CT passed away suddenly at home on August 30, 2017. Continually faced with many challenges since birth, Jonathan defied all odds and lived a long ...

Tellingly, O.J. did not deny the truth of our report that he recently had a stent inserted into heart — a device designed to improve blood flow and prevent further damage to the heart muscle.

Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-130. Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents ...

The role of bacterial adhesion and biofilm formation on stents in stent-associated UTIs is unclear and development of UTIs and their treatment might depend on patient immune status Encrustation ...

Patients take bloodthinners to prevent stent thrombosis ... which is a big market, but J&J and its partner Bayer AG have been hoping for a much wider use of the drug. There are 1.2 million ...

He went on to sue J&J/Cordis and Boston Scientific for patent infringement. In the Boston Scientific case, which involved that company's Taxus stents, both sides eventually settled for $50 million ...

Last week’s news that J&J is abandoning their coronary stent business was sad, but provided several lessons about poor product development execution and the need for constant innovation.